Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours - A prognostic test after surgical resection

Molecular Oncology

Volumn 9, Issue 6, 2015, Pages 1129-1139

  Kolberg, Matthias ^a,b   Høland, Maren ^a,b,c   Lind, Guro E ^a,b,c   Ågesen, Trude H ^a,b   Skotheim, Rolf I ^a,b   Sundby Hall, Kirsten ^a   Mandahl, Nils ^d   Smeland, Sigbjørn ^a,b   Mertens, Fredrik ^d   Davidson, Ben ^a,b   Lothe, Ragnhild A ^a,b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

BIRC5; Immunohistochemistry; MPNST; Prognosis; Survivin; TK1; TOP2A

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); SURVIVIN; THYMIDINE KINASE 1; BIRC5 PROTEIN, HUMAN; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; INHIBITOR OF APOPTOSIS PROTEIN; THYMIDINE KINASE; TUMOR ANTIGEN; TUMOR PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CHROMOSOME 17; CHROMOSOME ARM; FEMALE; GENE EXPRESSION PROFILING; GENOME ANALYSIS; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NEUROFIBROMATOSIS TYPE 1; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SCANDINAVIA; UPREGULATION; BIOSYNTHESIS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENOME-WIDE ASSOCIATION STUDY; METABOLISM; MIDDLE AGED; MORTALITY; NEURILEMMOMA; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEURILEMMOMA; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYMIDINE KINASE;

EID: 84929513324     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.02.005     Document Type: Article

References (62)

1. Alaggio R., Turrini R., Boldrin D., Merlo A., Gambini C., Ferrari A., Dall'Igna P., Coffin C.M., Martines A., Bonaldi L., De Salvo G.L., Zanovello P., Rosato A. Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST). Plos. One 2013, 8:e80456.
2. Aufderklamm S., Todenhofer T., Gakis G., Kruck S., Hennenlotter J., Stenzl A., Schwentner C. Thymidine kinase and cancer monitoring. Cancer Lett. 2012, 316:6-10.
3. Berner J.M., Sørlie T., Mertens F., Henriksen J., Sæter G., Mandahl N., Brogger A., Myklebost O., Lothe R.A. Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: studies of CDKN2A and other genes of the pRB pathway. Genes Chromosomes Cancer 1999, 26:151-160.
4. Bottillo I., Ahlquist T., Brekke H., Danielsen S.A., van den Berg E., Mertens F., Lothe R.A., Dallapiccola B. Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. J.Pathol. 2009, 217:693-701.
5. Brekke H.R., Kolberg M., Skotheim R.I., Hall K.S., Bjerkehagen B., Risberg B., Domanski H.A., Mandahl N., Liestol K., Smeland S., Danielsen H.E., Mertens F., Lothe R.A. Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. Neuro. Oncol. 2009, 11:514-528.
6. Brekke H.R., Ribeiro F.R., Kolberg M., Agesen T.H., Lind G.E., Eknaes M., Hall K.S., Bjerkehagen B., van den Berg E., Teixeira M.R., Mandahl N., Smeland S., Mertens F., Skotheim R.I., Lothe R.A. Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group. J.Clin. Oncol. 2010, 28:1573-1582.
7. Carroll S.L. Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol. 2012, 123:321-348.
8. Cichowski K., Shih T.S., Schmitt E., Santiago S., Reilly K., McLaughlin M.E., Bronson R.T., Jacks T. Mouse models of tumor development in neurofibromatosis type 1. Science 1999, 286:2172-2176.
9. De Raedt T., Beert E., Pasmant E., Luscan A., Brems H., Ortonne N., Helin K., Hornick J.L., Mautner V., Kehrer-Sawatzki H., Clapp W., Bradner J., Vidaud M., Upadhyaya M., Legius E., Cichowski K. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 2014, 514:247-251.
10. Du X., Yang J., Ylipaa A., Zhu Z. Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor. J.Hematol. Oncol. 2013, 6:93.
11. Fletcher C.D., Dal Cin P., De Wever I., Mandahl N., Mertens F., Mitelman F., Rosai J., Rydholm A., Sciot R., Tallini G., van den Berghe H., Vanni R., Willen H. Correlation between clinicopathological features and karyotype in spindle cell sarcomas. A report of 130 cases from the CHAMP study group. Am. J. Pathol. 1999, 154:1841-1847.
12. Ghadimi M.P., Young E.D., Belousov R., Zhang Y., Lopez G., Lusby K., Kivlin C., Demicco E.G., Creighton C.J., Lazar A.J., Pollock R.E., Lev D. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors. Clin. Cancer Res. 2012, 18:2545-2557.
13. Holtkamp N., Malzer E., Zietsch J., Okuducu A.F., Mucha J., Mawrin C., Mautner V.F., Schildhaus H.U., von Deimling A. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro Oncol. 2008, 10:946-957.
14. Holtkamp N., Reuss D.E., Atallah I., Kuban R.J., Hartmann C., Mautner V.F., Frahm S., Friedrich R.E., Algermissen B., Pham V.A., Prietz S., Rosenbaum T., Estevez-Schwarz L., von Deimling A. Subclassification of nerve sheath tumors by gene expression profiling. Brain Pathol. 2004, 14:258-264.
15. Huang d.W., Sherman B.T., Lempicki R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009, 37:1-13.
16. Karube K., Nabeshima K., Ishiguro M., Harada M., Iwasaki H. cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours. J.Clin. Pathol. 2006, 59:160-165.
17. Katz D., Lazar A., Lev D. Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Expert Rev. Mol. Med. 2009, 11:e30.
18. Keizman D., Issakov J., Meller I., Meimon N., Ish-Shalom M., Sher O., Merimsky O. Expression and significance of EGFR in malignant peripheral nerve sheath tumor. J.Neurooncol. 2009, 94:383-388.
19. Kinebuchi Y., Noguchi W., Igawa Y., Nishizawa O. Recurrent retroperitoneal malignant nerve sheath tumor associated with neurofibromatosis type 1 responding to carboplatin and etoposide combined chemotherapy. Int. J. Clin. Oncol. 2005, 10:353-356.
20. Koga T., Iwasaki H., Ishiguro M., Matsuzaki A., Kikuchi M. Frequent genomic imbalances in chromosomes 17, 19, and 22q in peripheral nerve sheath tumours detected by comparative genomic hybridization analysis. J.Pathol. 2002, 197:98-107.
21. Koga T., Iwasaki H., Ishiguro M., Matsuzaki A., Kikuchi M. Losses in chromosomes 17, 19, and 22q in neurofibromatosis type 1 and sporadic neurofibromas: a comparative genomic hybridization analysis. Cancer Genet. Cytogenet. 2002, 136:113-120.
22. Kolberg M., Høland M., Ågesen T.H., Brekke H.R., Liestøl K., Hall K.S., Mertens F., Picci P., Smeland S., Lothe R.A. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro. Oncol. 2013, 15:135-147.
23. Kresse S.H., Skarn M., Ohnstad H.O., Namlos H.M., Bjerkehagen B., Myklebost O., Meza-Zepeda L.A. DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH. Mol. Cancer 2008, 7:48.
24. Lee W., Teckie S., Wiesner T., Ran L.L., Granada C.N.P., Lin M.Y., Zhu S.N., Cao Z., Liang Y.P., Sboner A., Tap W.D., Fletcher J.A., Huberman K.H., Qin L.X., Viale A., Singer S., Zheng D.Y., Berger M.F., Chen Y., Antonescu C.R., Chi P. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat. Genet. 2014, 46:1227-1232.
25. Legius E., Marchuk D.A., Collins F.S., Glover T.W. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat. Genet. 1993, 3:122-126.
26. Levy P., Ripoche H., Laurendeau I., Lazar V., Ortonne N., Parfait B., Leroy K., Wechsler J., Salmon I., Wolkenstein P., Dessen P., Vidaud M., Vidaud D., Bieche I. Microarray-based identification of tenascin C and tenascin XB, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1. Clin. Cancer Res. 2007, 13:398-407.
27. Levy P., Vidaud D., Leroy K., Laurendeau I., Wechsler J., Bolasco G., Parfait B., Wolkenstein P., Vidaud M., Bieche I. Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. Mol. Cancer 2004, 3:20.
28. Lothe R.A., Karhu R., Mandahl N., Mertens F., Sæter G., Heim S., Børresen-Dale A.L., Kallioniemi O.P. Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis. Cancer Res. 1996, 56:4778-4781.
29. Lothe R.A., Smith-Sørensen B., Hektoen M., Stenwig A.E., Mandahl N., Saeter G., Mertens F. Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors. Genes Chromosomes Cancer 2001, 30:202-206.
30. Lothe R.A., Slettan A., Saeter G., Brogger A., Børresen A.L., Nesland J.M. Alterations at chromosome 17 loci in peripheral nerve sheath tumors. J.Neuropathol. Exp. Neurol. 1995, 54:65-73.
31. Menon A.G., Anderson K.M., Riccardi V.M., Chung R.Y., Whaley J.M., Yandell D.W., Farmer G.E., Freiman R.N., Lee J.K., Li F.P. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc. Natl. Acad. Sci. U. S. A 1990, 87:5435-5439.
32. Mertens F., Dal Cin P., De Wever I., Fletcher C.D., Mandahl N., Mitelman F., Rosai J., Rydholm A., Sciot R., Tallini G., van den Berghe H., Vanni R., Willen H. Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group. J.Pathol. 2000, 190:31-38.
33. Miller S.J., Rangwala F., Williams J., Ackerman P., Kong S., Jegga A.G., Kaiser S., Aronow B.J., Frahm S., Kluwe L., Mautner V., Upadhyaya M., Muir D., Wallace M., Hagen J., Quelle D.E., Watson M.A., Perry A., Gutmann D.H., Ratner N. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res. 2006, 66:2584-2591.
34. Nielsen G.P., Stemmer-Rachamimov A.O., Ino Y., Moller M.B., Rosenberg A.E., Louis D.N. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am. J. Pathol. 1999, 155:1879-1884.
35. Nielsen G., Antonescu C.R., Lothe R.A. Malignant peripheral nerve sheath tumour. WHO Classification of Tumours of Soft Tissue and Bone 2013, 187-189. International Agency for Research on Cancer, Lyon, France. C.D.M. Fletcher, J.A. Bridge, P.C.W. Hogendoorn, F. Mertens (Eds.).
36. Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., Bigner S.H., Davidson N., Baylin S., Devilee P., et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989, 342:705-708.
37. Oliveira G., Greco R., Lupo-Stanghellini M.T., Vago L., Bonini C. Use of TK-cells in haploidentical hematopoietic stem cell transplantation. Curr. Opin. Hematol. 2012, 19:427-433.
38. Packer R.J., Raffel C., Villablanca J.G., Tonn J.C., Burdach S.E., Burger K., LaFond D., McComb J.G., Cogen P.H., Vezina G., Kapcala L.P. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J.Neurosurg. 2000, 92:249-254.
39. Patel A.V., Eaves D., Jessen W.J., Rizvi T.A., Ecsedy J.A., Qian M.G., Aronow B.J., Perentesis J.P., Serra E., Cripe T.P., Miller S.J., Ratner N. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target. Clin. Cancer Res. 2012, 18:5020-5030.
40. Peacock J.D., Cherba D., Kampfschulte K., Smith M.K., Monks N.R., Webb C.P., Steensma M. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. J.Transl. Med. 2013, 11:213.
41. Rahrmann E.P., Moriarity B.S., Otto G.M., Watson A.L., Choi K., Collins M.H., Wallace M., Webber B.R., Forster C.L., Rizzardi A.E., Schmechel S.C., Ratner N., Largaespada D.A. Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis. Am. J. Pathol. 2014, 184:2082-2098.
42. Rahrmann E.P., Watson A.L., Keng V.W., Choi K., Moriarity B.S., Beckmann D.A., Wolf N.K., Sarver A., Collins M.H., Moertel C.L., Wallace M.R., Gel B., Serra E., Ratner N., Largaespada D.A. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat. Genet. 2013, 45:756-766.
43. Ryan B.M., O'Donovan N., Duffy M.J. Survivin: a new target for anti-cancer therapy. Cancer Treat. Rev. 2009, 35:553-562.
44. Sasaki T., Lopes M.B., Hankins G.R., Helm G.A. Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system. Acta Neuropathol. 2002, 104:105-109.
45. Schmidt H., Taubert H., Meye A., Wurl P., Bache M., Bartel F., Holzhausen H.J., Hinze R. Gains in chromosomes 7, 8q, 15q and 17q are characteristic changes in malignant but not in benign peripheral nerve sheath tumors from patients with Recklinghausen's disease. Cancer Lett. 2000, 155:181-190.
46. Schmidt H., Wurl P., Taubert H., Meye A., Bache M., Holzhausen H.J., Hinze R. Genomic imbalances of 7p and 17q in malignant peripheral nerve sheath tumors are clinically relevant. Genes Chromosomes Cancer 1999, 25:205-211.
47. Sedani A., Cooper D.N., Upadhyaya M. An emerging role for microRNAs in NF1 tumorigenesis. Hum. Genomics 2012, 6:23.
48. Sioud M., Sæbøe-Larssen S., Hetland T.E., Kærn J., Mobergslien A., Kvalheim G. Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients. Int. J. Oncol. 2013, 43:280-288.
49. Skotheim R.I., Kallioniemi A., Bjerkhagen B., Mertens F., Brekke H.R., Monni O., Mousses S., Mandahl N., Soeter G., Nesland J.M., Smeland S., Kallioniemi O.P., Lothe R.A. Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. J.Clin. Oncol. 2003, 21:4586-4591.
50. Steins M.B., Serve H., Zuhlsdorf M., Senninger N., Semik M., Berdel W.E. Carboplatin/etoposide induces remission of metastasised malignant peripheral nerve tumours (malignant schwannoma) refractory to first-line therapy. Oncol. Rep. 2002, 9:627-630.
51. Storlazzi C.T., Brekke H.R., Mandahl N., Brosjo O., Smeland S., Lothe R.A., Mertens F. Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours. J.Pathol. 2006, 209:492-500.
52. Tabone-Eglinger S., Bahleda R., Cote J.F., Terrier P., Vidaud D., Cayre A., Beauchet A., Theou-Anton N., Terrier-Lacombe M.J., Lemoine A., Penault-Llorca F., Le Cesne A., Emile J.F. Frequent EGFR positivity and overexpression in high-grade areas of human MPNSTs. Sarcoma 2008, 2008(849156). 849156.
53. Verdijk R.M., den Bakker M.A., Dubbink H.J., Hop W.C., Dinjens W.N., Kros J.M. TP53 mutation analysis of malignant peripheral nerve sheath tumors. J.Neuropathol. Exp. Neurol. 2010, 69:16-26.
54. Vogel K.S., Klesse L.J., Velasco-Miguel S., Meyers K., Rushing E.J., Parada L.F. Mouse tumor model for neurofibromatosis type 1. Science 1999, 286:2176-2179.
55. Watson M.A., Perry A., Tihan T., Prayson R.A., Guha A., Bridge J., Ferner R., Gutmann D.H. Gene expression profiling reveals unique molecular subtypes of neurofibromatosis type I-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol. 2004, 14:297-303.
56. Wu J., Patmore D.M., Jousma E., Eaves D.W., Breving K., Patel A.V., Schwartz E.B., Fuchs J.R., Cripe T.P., Stemmer-Rachamimov A.O., Ratner N. EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene 2014, 33:173-180.
57. Xie C., Yao M., Dong Q. Proliferating cell unclear antigen-associated factor (PAF15): a novel oncogene. Int. J. Biochem. Cell. Biol. 2014, 50:127-131.
58. Yang J., Ylipaa A., Sun Y., Zheng H., Chen K., Nykter M., Trent J., Ratner N., Lev D.C., Zhang W. Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment. Clin. Cancer Res. 2011, 17:7563-7573.
59. Yu J., Deshmukh H., Payton J.E., Dunham C., Scheithauer B.W., Tihan T., Prayson R.A., Guha A., Bridge J.A., Ferner R.E., Lindberg G.M., Gutmann R.J., Emnett R.J., Salavaggione L., Gutmann D.H., Nagarajan R., Watson M.A., Perry A. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin. Cancer Res. 2011, 17:1924-1934.
60. Zhang M., Wang Y.X., Jones S., Sausen M., McMahon K., Sharma R., Wang Q., Belzberg A.J., Chaichana K., Gallia G.L., Gokaslan Z.L., Riggins G.J., Wolinksy J.P., Wood L.D., Montgomery E.A., Hruban R.H., Kinzler K.W., Papadopoulos N., Vogelstein B., Bettegowda C. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat. Genet. 2014, 46:1170-1172.
61. Zhu Y., Parada L.F. The molecular and genetic basis of neurological tumours. Nat. Rev. Cancer 2002, 2:616-626.
62. Zou C., Smith K.D., Liu J., Lahat G., Myers S., Wang W.L., Zhang W., McCutcheon I.E., Slopis J.M., Lazar A.J., Pollock R.E., Lev D. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann. Surg. 2009, 249:1014-1022.